ARQULE INC Form 8-K March 22, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2016

ARQULE, INC.

(Exact Name of Issuer as Specified in Charter)

Delaware 000-21429 04-3221586

(State or other jurisdiction (Commission File Number) (I.R.S. Employer


of Identification

incorporation) No.)

One Wall Street

Burlington, MA 01803

Edgar Filing: ARQULE INC - Form 8-K



[&]quot;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[&]quot;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[&]quot;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[&]quot;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ARQULE INC - Form 8-K

Section 8 - Other Events
Item 8.01. Other Events.
ArQule, Inc. (the "Registrant") and Daiichi Sankyo today announced that the independent data monitoring committee of the METIV-HCC study conducted the planned interim assessment, and it was determined the trial will continue to its final analysis.
The Registrant's press release dated March 22, 2016, a copy of which is attached hereto as Exhibit 99.1, is incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. 99.1 Text of press release announcing interim clinical trial results dated March 22, 2016
2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARQULE, INC. (Registrant)

/s/ Peter S. Lawrence Peter S. Lawrence President and Chief Operating Officer

March 22, 2016

3